KHKengo Hanaya

Kengo Hanaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kengo Hanaya has a total of 82 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Stepwise dual N-terminal modification of proteins via nickel(II)-mediated aldol and Pictet–Spengler reactions

    by Kengo Hanaya, Yuki Morimi, Shoma Usui, Kazuaki Taguchi, Yuki Wada, Masaki Kawano, Shuhei Higashibayashi, Takeshi Sugai


  • Open Access

    Stepwise Dual N-Terminal Modification of Proteins via Nickel(II)-Mediated Aldol and Pictet–Spengler Reactions

    by Kengo Hanaya, Yuki Morimi, Shoma Usui, Kazuaki Taguchi, Yuki Wada, Masaki Kawano, Shuhei Higashibayashi, Takeshi Sugai

    The dual modification of proteins with two distinct artificial functionalities significantly broadens the scope and utility of protein conjugates. To achieve this, it is necessary to perform site-specific and stoichiometrically controlled modifications, for which the N-terminus is a promising target owing to its unique accessibility and chemical reactivity. In this study, a sequential N-terminal dual-modification strategy was developed that combines a nickel(II)-mediated aldol reaction (using imidazo[1,2-a]pyridine-2-carbaldehyde derivatives) with a subsequent Pictet–Spengler reaction (using 2-pyridinecarboxaldehyde derivatives) at the N-terminus. Both transformations employ structurally simple, readily accessible reagents and proceed under mild, non-denaturing aqueous conditions (pH 7 and 5.5, 37 °C). Using this approach, the dual modification of myoglobin and trastuzumab was achieved. The resulting trastuzumab conjugate, bearing Cy5 (a fluorescent dye) and monomethyl auristatin E (a potent cytotoxic agent), retained the ability to recognize human epidermal growth factor receptor 2 (HER2) and exhibited potent cytotoxicity against HER2-positive cancer cell lines. This sequential method established the N-terminus as a versatile alternative to cysteine for dual functionalization, enabling the creation of well-defined multifunctional protein conjugates using simple, modular chemistry.

  • Open Access

    One‐Step Maleimide‐Based Dual Functionalization of Protein N‐Termini

    by Kengo Hanaya, Kazuaki Taguchi, Yuki Wada, Masaki Kawano

    Maleimide derivatives are privileged reagents for chemically modifying proteins through the Michael addition reaction with cysteine due to their selectivity, operational simplicity, and commercial availability. However, since accessible free cysteine is rarely found in natural proteins, it is highly desirable to find alternative targets to enable direct bioconjugation of proteins with maleimides. In this study, we have developed an operationally simple and straightforward method for the N‐terminal modification of proteins without the need for mutagenesis via a copper(II)‐mediated [3+2] cycloaddition reaction with maleimides and 2‐pyridinecarboxaldehyde (2‐PCA) derivatives under non‐denaturing conditions at pH 6 and 37 °C in aqueous media. Our method utilizes commercially available maleimides to attach diverse functionalities to various N‐terminal amino acids. We demonstrate the preparation of a ternary protein complex cross‐linked at the N‐termini and dually modified trastuzumab equipped with monomethyl auristatin E (MMAE), a cytotoxic agent, and a Cy5 fluorophore (MMAE‐Cy5‐trastuzumab). MMAE‐Cy5‐trastuzumab retained human epidermal growth factor receptor 2 (HER2) recognition activity and exerted cytotoxicity against HER2‐positive cells. Furthermore, MMAE‐Cy5‐trastuzumab allowed successful visualization of HER2‐positive cancer cells in mouse tumors. This straightforward method will expand the accessibility of protein conjugates with well‐defined structures in a wide range of research fields.


  • Open Access

    One‐Step Maleimide‐Based Dual Functionalization of Protein N‐Termini

    by Kengo Hanaya, Kazuaki Taguchi, Yuki Wada, Masaki Kawano

    Maleimide derivatives are privileged reagents for chemically modifying proteins through the Michael addition reaction with cysteine due to their selectivity, operational simplicity, and commercial availability. However, since accessible free cysteine is rarely found in natural proteins, it is highly desirable to find alternative targets to enable direct bioconjugation of proteins with maleimides. In this study, we have developed an operationally simple and straightforward method for the N‐terminal modification of proteins without the need for mutagenesis via a copper(II)‐mediated [3+2] cycloaddition reaction with maleimides and 2‐pyridinecarboxaldehyde (2‐PCA) derivatives under non‐denaturing conditions at pH 6 and 37 °C in aqueous media. Our method utilizes commercially available maleimides to attach diverse functionalities to various N‐terminal amino acids. We demonstrate the preparation of a ternary protein complex cross‐linked at the N‐termini and dually modified trastuzumab equipped with monomethyl auristatin E (MMAE), a cytotoxic agent, and a Cy5 fluorophore (MMAE‐Cy5‐trastuzumab). MMAE‐Cy5‐trastuzumab retained human epidermal growth factor receptor 2 (HER2) recognition activity and exerted cytotoxicity against HER2‐positive cells. Furthermore, MMAE‐Cy5‐trastuzumab allowed successful visualization of HER2‐positive cancer cells in mouse tumors. This straightforward method will expand the accessibility of protein conjugates with well‐defined structures in a wide range of research fields.


  • Open Access

    Copper(II)-mediated N-terminal modification of proteins with maleimide derivatives

    by Kengo Hanaya, Kazuaki Taguchi, Yuki Wada, Masaki Kawano, Shuhei Higashibayashi

    Maleimide derivatives are privileged reagents for the chemical modification of proteins via the Michael addition of cysteine due to their selectivity, reaction rate, and commercial availability. Since accessible free cysteine is rarely found in natural proteins, an alternative target for maleimide derivatives is highly desirable for direct bioconjugation. In this study, we developed a copper(II)-mediated [3+2] cycloaddition reaction with maleimide and 2-pyridinecarboxaldehyde (2-PC) derivatives as an operationally simple and powerful method for the N-terminal modification of peptides and proteins. This method utilizes commercially available maleimides to attach diverse functionalities to various N-terminal amino acids. The combined use of copper(II) ions and heteroaromatic aldehydes is key to the selective formation of azomethine intermediates at the N-terminus in aqueous media under mild conditions, achieving high N-terminal selectivity. We demonstrate the preparation of a ternary protein complex cross-linked at the N-termini and dually modified trastuzumab equipped with monomethyl auristatin E (MMAE), a cytotoxic agent, and a Cy5 fluorophore (MMAE–Cy5–trastuzumab). The MMAE–Cy5–trastuzumab retained human epidermal growth factor receptor 2 (HER2) recognition activity and exerted cytotoxicity against HER2-positive cells. Furthermore, MMAE–Cy5–trastuzumab helped successfully visualize HER2-positive cancer cells in mouse tumors. This straightforward method will enhance the accessibility and utility of protein conjugates with defined structures across a diverse spectrum of researchers.

  • Dual delivery of carbon monoxide and doxorubicin using haemoglobin–albumin cluster: proof of concept for well-tolerated cancer therapy

    by Chihiro Ito, Kazuaki Taguchi, Taiga Yamada, Kengo Hanaya, Yuki Enoki, Takeshi Sugai, Teruyuki Komatsu, Kazuaki Matsumoto

    A serious concern of doxorubicin (DOX) therapy is that it causes severe adverse effects, particularly cardiotoxicity. Carbon monoxide (CO) possesses powerful cytoprotective effects against drug-induced organ injury and is expected to ameliorate DOX-induced cardiotoxicity. In this study, a dual carrier of DOX and CO (CO-HemoAct-DOX) was fabricated based on a haemoglobin–albumin cluster (HemoAct), which is a protein cluster with a haemoglobin core structure wrapped by serum albumin. CO-HemoAct-DOX was synthesised by binding CO to a haemoglobin core and covalently conjugating (6-maleimidocaproyl)hydrazone derivative of DOX to an albumin shell. The average DOX/cluster ratio was about 2.6. In the in vitro cytotoxicity assay against cancer cells, the anti-tumour activity of CO-HemoAct-DOX was 10-fold lower than that of DOX in a 2D-cultured model, whereas CO-HemoAct-DOX suppressed the growth of tumour spheroids to the same extent as DOX in the 3D-cultured model. In colon-26 tumour-bearing mice, CO-HemoAct-DOX achieved DOX delivery to the tumour site and alleviated tumour growth more effectively than DOX. Furthermore, CO-HemoAct attenuated DOX-induced cardiomyocyte atrophy in H9c2 cells and elevated the levels of cardiac biomarkers in mice exposed to DOX. These results suggest that the dual delivery of CO and DOX using HemoAct is a promising strategy as an anti-tumour agent to realise well-tolerated cancer therapy with minimal cardiotoxicity.


  • Selective modification of tryptophan in polypeptides via C–N coupling with azoles using in situ-generated iodine-based oxidants in aqueous media

    by Shunsuke Watanabe, Yuki Wada, Masaki Kawano, Shuhei Higashibayashi, Takeshi Sugai, Kengo Hanaya

    This study demonstrates the C–N coupling of tryptophan with azoles, promoted by an in situ-generated iodine-based oxidant. The protocol was successfully applied to the selective modification of tryptophan in nonprotected polypeptide bearing oxidatively sensitive residues in acidic aqueous media. The present method allows the attachment of reactive handles to polypeptides and the peptide stapling.


  • Open Access

    Inversion of Diaza[5]Helicenes Through an N−N Bond Breaking Pathway

    by Toshifumi Kobayashi, Fumitaka Ishiwari, Takanori Fukushima, Yuki Nojima, Masashi Hasegawa, Yasuhiro Mazaki, Kengo Hanaya, Takeshi Sugai, Shuhei Higashibayashi

    1,1’,10,10’‐Biphenothiazine and its S,S,S’,S’‐tetroxide are diaza[5]helicenes with N−N linkages. Kinetic experiments on racemization together with DFT calculations revealed that they undergo inversion through the N−N bond breaking pathway rather than the general conformational pathway. In these diaza[5]helicenes with this inversion mechanism, the reduction of electronic repulsion in the N−N bond by modification of S to SO2 at the outer position of the helix led to a significantly higher inversion barrier, 35.3 kcal/mol, compared to [5]helicene. 1,1’,10,10’‐Biphenothiazine S,S,S’,S’‐tetroxide was highly resistant to acid‐mediated N−N bond breaking and racemization under acidic conditions.


  • Copper‐Catalyzed Stereoselective Borylation and Palladium‐Catalyzed Stereospecific Cross‐Coupling to Give Aryl C‐Glycosides

    by Kazuki Kurahayashi, Kengo Hanaya, Takeshi Sugai, Go Hirai, Shuhei Higashibayashi

    Metabolically stable C‐glycosides are an essential family of compounds in bioactive natural products, therapeutic agents, and biological probes. For their application, development of synthetic methods by connecting glycosides and aglycons with strict stereocontrol at the anomeric carbon, as well as with high functional‐group compatibility and environmental compatibility is a pivotal issue. Although Suzuki–Miyaura‐type C(sp3)−C(sp2) cross‐coupling using glycosyl boronates is a potential candidate for the construction of C‐glycosides, neither the cross‐coupling itself nor the facile synthesis of the coupling precursor, glycosyl boronates, have been achieved to date. Herein, it was succeeded to develop a copper‐catalyzed stereoselective one‐step borylation of glycosyl bromides to glycosyl boronates and palladium‐catalyzed stereospecific cross‐coupling of β‐glycosyl borates with aryl bromides to give aryl β‐C‐glycosides, in which the β‐configuration of the anomeric carbon of the glycosyl trifluoroborates is stereoretentively transferred to that of the resulting aryl C‐glycosides.